Floatz logo

Glucose-Dependent Insulinotropic Polypeptide

Spinal Muscular Atrophy (SMA)

University of Copenhagenprotein_peptideN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

21 Active assets in the Spinal Muscular Atrophy (SMA) cohort.

Asset / SponsorPhaseRating
Nusinersen
Scholar Rock, Inc.
Phase 4A
Risdiplam
Scholar Rock, Inc.
Phase 4A
NON-REPLICATING RECOMBINANT SELF-COMPLEMENTARY (SC) ADENO-ASSOCIATED VIRUS SEROTYPE 9 (AAV9) VECTOR CONTAINING THE CDNA OF THE SURVIVAL OF MOTOR NEURON 2 (SMN2) GENE UNDER THE CONTROL OF THE HYBRID CYTOMEGALOVIRUS (CMV) ENHANCER/CHICKEN BETA-ACTIN PROMOTER (CBA)
Novartis Pharmaceuticals
Phase 4A
oav101
Novartis Pharmaceuticals
Phase 4BBB
Srk-015
Scholar Rock, Inc.
Phase 3BB

View all 40 →

Same molecule, other indications

Glucose-Dependent Insulinotropic Polypeptide is also rated in:

type 2 diabetes mellitusDormant
CCC
Indicative ·
48 / 100
View asset →
fatty liver diseaseDormant
CCC
Indicative ·
48 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →